Users Discontinuing Slimming Jabs Regain Weight Far More Rapidly Compared to Those on Conventional Diets

Fresh analysis suggests that individuals who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt conventional diet and exercise programs.

Research printed in a leading medical journal shows that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such drugs should be informed of the potential of quick rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.

This pace of recovery suggests a reversion to original weight in about a year and a half.

Comparing Therapies

The research, which looked at 37 of trials involving over 9,000 of patients, compared the outcomes of these new drugs with conventional dieting.

The team point out that individuals who lose weight through diet and exercise typically experience a more gradual weight regain—approximately 100 grams monthly—post-intervention.

Understanding the Fast Regain

Experts suggest the mode of action of the jabs is key to understanding the accelerated weight return.

These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.

"Sustained high doses of the hormone levels several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.

"Withdrawal of this hormone supplement means appetite is no longer kept in check, making overeating much more probable."

A Lifelong Condition?

Medical guidelines advise the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.

Professionals contend that, due to the significant potential of weight regain, the treatment is often life-long.

This opinion is reinforced by drug manufacturers, who say that the findings "emphasize the long-term character of excess weight," similar to managing diseases like high blood pressure.

Patient Experiences

People who have discontinued the jabs describe a intense return of appetite.

"It felt as if something flipping and you're instantly ravenous," described a patient.

This difficulty is compounded if patients have not developed sustainable dietary or behavioural changes during therapy.

Growing Use

Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with demand remaining high.

• Adoption is higher among females compared to males.
• The 40s and 50s age group shows the greatest level of interest.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

Ultimately, clinicians stress that while these medications are potent tools for shedding pounds, they are not a permanent fix and maintained weight loss relies on integrated lifestyle changes.